* Aprea Therapeutics Inc APRE.OQ reported a quarterly
adjusted
loss of $1.34 per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of $1.50 per share.
* Reported revenue was zero; analysts expected zero.
* Aprea Therapeutics Inc's reported EPS for the quarter was
a loss
of $1.34.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
* Aprea Therapeutics Inc shares had fallen by 11.0% this
quarter and lost 40.3% so far this year.
* The company reported a quarterly loss of $4.38 million.
* Wall Street's median 12-month price target for Aprea
Therapeutics Inc is $16.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data May
15 at 09:20 p.m. UTC. All figures in US dollars unless
otherwise stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2023 -1.50 -1.34 Beat
Dec. 31 2022 -3.08 -0.92 Beat
Sep. 30 2022 -5.50 -2.40 Beat
Jun. 30 2022 -7.50 -19.60 Missed